We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

HNGE:NYSEHinge Health, Inc. Analysis

Data as of 2026-08-17 - not real-time

$88.49

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

The moving-average structure behind Hinge Health, Inc. is bullish at $88.49, with short-term averages leading the long-term ones. Across the trailing 30 sessions it gained 5.3%. Relative strength is 62.1 — approaching overbought — and the MACD signal is bullish. Watch $71.40 as support and $93.13 as the nearer resistance level.
Multiples put this in undervalued territory: 10.8 times earnings against the sector's 29.8. Analyst price targets sit 20.3% above the current price. Revenue is growing at 53.0% on a 15.1% profit margin.
On a 1-10 scale the risk profile lands at 7 — elevated. With 30-day volatility of 51.5%, a beta of 1.13 and a maximum drawdown of 48.0%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 95 on the fear-greed composite.
The horizons line up on buy — conviction 8 out of 10.

Top Market Events

Meridian Funds, managed by ArrowMark Partners, released its second-quarter 2026 investor letter for “Meridian Small...12dHinge Health forecasts $856M-$860M 2026 revenue as it plans broader GI rollout in 2027Q2 2026 earnings call: revenue...Hinge Health Inc. HNGE saw its shares surge in the last session with trading volume being higher than average. The...

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 8/10

Key Factors

  • Short-term moving averages stacked above long-term ones
  • Trading above the 200-day average of 53.51
  • MACD momentum is positive

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Short-term moving averages stacked above long-term ones
  • P/E of 10.8 versus sector average of 29.8
  • Trading above the 200-day average of 53.51

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • P/E of 10.8 versus sector average of 29.8
  • Analyst targets imply +20.3% versus the current price
  • Profit margin of 15.1% is healthy

Key Metrics & Analysis

Financial Health

Revenue Growth53.00%
Profit Margin15.15%
P/E Ratio10.8
ROE30.38%
ROA7.70%
Debt/Equity1.71
P/B Ratio20.6
Op. Cash Flow$290.8M
Free Cash Flow$299.6M
Industry P/E29.8

Technical Analysis

TrendBullish
RSI62.1
Support$71.40
Resistance$93.13
MA 20$81.32
MA 50$78.48
MA 200$53.51
MACDBullish
VolumeIncreasing
Fear & Greed Index94.75

Valuation

Fair Value$135.62
Target Price$106.47
Upside/Downside20.31%
GradeUndervalued
TypeGrowth

Risk Assessment

Beta1.13
Volatility51.46%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.